PATENT CLAIM ANALYSIS

Application Number: 15778368
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "218100"]

Abstract:
A highly safe dengue vaccine was invented that induced a neutralizing antibody response against all of the four serotypes of dengue virus without developing more than a fixed level of viremia with single administration. A tetravalent dengue virus formulation is provided that is excellent in both efficacy (neutralizing antibody response) and safety (viremia).

Claim (Index 19):
The attenuated serotype 2 dengue virus of  claim 13  wherein the mutation at position 143 is D143N, the mutation at position 400 is T400K, the mutation at position 1102 is D1102N, the mutation at position 1308 is L1308F, and the mutation at position 1654 is E1654K.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 93.0
- Lexical Diversity: 1.37209
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15195820', '11449876', '11453344', '13212845', '13281240']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7414522791532671
- 35 USC 102 Novelty (BERT): 0.5441484065317481
- Combined Prediction Score: 0.7217218918911151
- Mean Citation Score: 370.044854
- Max Citation Score: 379.45105
- Similarity Product: 284.488546331352

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test